Bolt Biotherapeutics, Inc.
4 clinical trials · Sponsor
◉ Watch Bolt Biotherapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer (NCT05954143) | Bolt Biotherapeutics, Inc. | 2023-11-30 |
| Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies (NCT06052852) | Bolt Biotherapeutics, Inc. | 2023-10-11 |
| A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors (NCT04278144) | Bolt Biotherapeutics, Inc. | 2020-02-24 |
Track Bolt Biotherapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.